Extracorporeal Membrane Oxygenation Machine Market: Recent Developments
ECMO was initially used in 1970s, however, the initial high rates of mortality and less than optimal success rates negatively influenced the wider acceptance of ECMO until the H1N1 outbreak of 2009. ECMO was used in 2009 global H1N1 influenza epidemic and patients were treated for H1N1 related- Acute Respiratory Distress Syndrome (ARDS). It provided fruitful results for majority of the patients treated with ECMO.
Chinese Hospital in Wuhan has used an ECMO machine to save a critically-ill coronavirus patient by bypassing heart and lungs and helping the patient to recover. As coronavirus attacks lung predominantly, turning it into virus lungs; Bypassing the lungs which were filled with the liquid, helped it to recover well.
Utility of ECMO device has been proven and are crucial in dealing with heart attacks and acute heart failures. These numbers suggest the growing requirement for ECMO device. Growing awareness regarding the device is set to enhance the growth in the ECMO device market.
ECMO had provided much better results in Neonatal & Pediatric populations and are much readily adopted in that concern. Single-institution retrospective studies and multi-institutional registries have reported survival rates ranging from 40%-80% in neonatal (0–30 days) and pediatric populations with respiratory indications generally having better outcomes. Apart from this, its usage for adult respiratory failure is rapidly increasing as well.